We want to improve the safety and efficacy of pharmacotherapy for every European patient by enabling clinical pharmacogenomics
Shared European Guidelines
Maintenance and dissemination of pharmacogenomics guidelines in the European Union
Implementation and Evaluation
Clinical implementation and outcome evaluation of pre-emptive pharmacogenomics in a multitude of European countries
Development of powerful and barrier-free clinical decision support systems and novel pharmacogenomics methodologies
Communication and education
Development of a program to reach out to patients, health care professionals, regulatory agencies, politics and health insurance organisations
Pharmacogenomics (PGx) is the study of genetic variability affecting an individual’s response to a drug. Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.
The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).
50% of elderly patients will receive drug treatment that could be optimized via PGx within the next four years.
98% of physicians think that PGx could help to better predict drug response.
Lack of knowledge
Only 10% of physicians feel they currently have adequate knowledge and tools for PGx.
A strong and efficient team of expert researchers, clinicians, companies and stakeholders
Sir Munir Pirmohamed
Cristina Lucía Dávila-Fajardo
George P. Patrinos
Wendy van Hemmen
Cathelijne van der Wouden
Mandy van Rhenen
Frans van der Vaart
The first annual U-PGx consortium meeting will take place in Athens on September 27-28, 2016. Meeting venue: The Divani Palace Acropolis hotel, Athens, Greece.
Click here to read the full the PharmGKB blog.
Mary Relling is a scientist at St. Jude Children’s Research Hospital where she is a member of the St. Jude Faculty, chair of the Pharmaceutical Sciences Department and she leads the CPIC initiative.
We thank all participants for making a very productive kick-off meeting possible and look ahead towards a busy first year!
On the 19th and 20th January 2016, the kick-off meeting marked the start of the U-PGx project and was attended by 35 participating researchers and clinicians from 10 EU countries. Agenda 19 January 13:00 – 17:00 “Systems pharmacology and Drug-drug interactions”, organized by Matthias Schwab 15:00 – 17:00 “ICT tools and PGx infrastructure”, organized by Matthias[…]
We are excited to report that the U-PGx proposal PHC-24-2015 – Piloting personalised medicine in health and care systems has been favourably evaluated by the Commission in stage 2 evaluations. The project will have a funding volume of 14,9 million Euros and a duration of 60 months. The grant agreement is expected to be finalised[…]
Again, we thank all participants for an enjoyable and productive meeting!
Attendance and reservations Meeting agenda (March 22) 8:45 – 9:00 Arrival at meeting room (CeMSIIS, Spitalgasse 23, BT88, third floor) 9:00 – 9:20 Welcome at Medical University of Vienna, introduction, overview of goals and schedule of the meeting, overview of current state of the proposal 9:20 – 9:50: Presentation and discussions of decisions made regarding[…]
We thank all attendees for a very enjoyable and productive meeting.
Russ Altman is a scientist at Stanford University Medical School, where he is chair of the department of Bioengineering and director of the program in Biomedical Informatics.